The estimated Net Worth of Colleen F Reitan is at least $12.9 million dollars as of 3 September 2024. Ms. Reitan owns over 46,012 units of Alnylam Pharmaceuticals Inc stock worth over $11,139,818 and over the last 6 years she sold ALNY stock worth over $1,286,035. In addition, she makes $470,707 as Independent Director at Alnylam Pharmaceuticals Inc.
Colleen has made over 1 trades of the Alnylam Pharmaceuticals Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she sold 46,012 units of ALNY stock worth $1,286,035 on 3 September 2024.
The largest trade she's ever made was selling 46,012 units of Alnylam Pharmaceuticals Inc stock on 3 September 2024 worth over $1,286,035. On average, Colleen trades about 3,539 units every 0 days since 2018. As of 3 September 2024 she still owns at least 42,533 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Ms. Reitan stock trades at the bottom of the page.
Colleen F. Reitan is an Independent Director of the Alnylam Pharmaceuticals, Inc. Ms. Reitan served as President of Plan Operations of Health Care Service Corporation, or HCSC, the largest customer-owned health insurer in the United States and an independent licensee of Blue Cross and Blue Shield Association from October 2008 to April 2018. While at HCSC, she also served as the company’s Chief Operating Officer from January 2009 to January 2015. Previously, Ms. Reitan served as President and Chief Operating Officer of Blue Cross Blue Shield of Minnesota from 2006 to 2008.
As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of Colleen Reitan at Alnylam Pharmaceuticals Inc is $470,707. There are 17 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.
Colleen Reitan is 60, she's been the Independent Director of Alnylam Pharmaceuticals Inc since 2018. There are 10 older and 10 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.
Colleen's mailing address filed with the SEC is 320, Wakara Way, U of U Research Park, Salt Lake City, Salt Lake County, Utah, 84108, United States.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal et Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: